Onkologie. 2010:4(3):154-158

Therapy in Hodgkin´s lymphoma

Zdeněk Král
Interní hematoonkologická klinika FN Brno

Treatment strategy in Hodgkin´s lymphoma (HL) is based on randomized trials. In the early favourable stages of HL is a standard combination

of two chemotherapy cycles ABVD followed by 20 Gy involved field radiotherapy. In the early unfavourable stages of HL is a standard

combination of four chemotherapy cycles followed by 30 Gy involved field radiotherapy (recommendation of German Hodgkin Study

Group – GHSG). In the advanced stages of HL the achieved satisfactory results with eight chemotherapy cycles BEACOPP escalated. Highdose

chemotherapy with autologous stem cell transplantation is the standard treatment for patients with relapsed or refractory HL.

Keywords: Hodgkin lymphoma, high-dose therapy, autologous stem cell transplantation

Published: July 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Král Z. Therapy in Hodgkin´s lymphoma. Onkologie. 2010;4(3):154-158.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Küppers R. Molecular biology of Hodgkin's lymphoma. Adv Cancer Res. 2002; 84: 277-312. Go to original source... Go to PubMed...
    2. Jaffe ES, Hartus NL, Stein H, et al. World Health Organization Classification of Tumors. Pathology and Genetics of Tumor of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon 2001: 351.
    3. Duggan D, Petroni G, Johnson J, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin´s disease: report of an intergroup trial. J Clin Oncol 2003; 21(4): 607-614. Go to original source... Go to PubMed...
    4. Kaplan HS. Hodgkin's disease: biology, treatment, prognosis. Blood, 1981; 57: 813-822. Go to original source...
    5. Tubiana M, Henry-Amar M, Carde P, et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin´s disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987. Blood, 1989; 73: 47-56. Go to original source...
    6. Engert A, Franclin, J, Eich HT, et al. Two cykles of Doxorubicin, Bleomycin, Vinblastin, and Dacarbazin Plus ExtendedField Radiotherapy Is superior to Radiotherapy Alone in Early Favourable Hodgkin´s lymphoma: Final Results of the GHSG HD7 trial. J Clin Oncol 2007; 25(23): 3495-3502. Go to original source... Go to PubMed...
    7. Sieniawski M, Franklin J, Nogova L, et al. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma. J Clin Oncol, 2007; 25(15): 2000-2005. Go to original source... Go to PubMed...
    8. Noordijk EM, Thomas J, Fermé C, et al. First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favourable or unfavourable early stage Hodgkin's lymphoma (HL). J Clin Oncol 2005; 23(1 Supplement): 6505. Go to original source...
    9. Meyer RM, Gospodarowicz KM, Connors JM, et al. Randomized Comparison of ABVD Chemotherapy With a Strategy That Includes Radiation Therapy in Patients With Limited-Stage Hodgkin's Lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 2(3): 4634-4642. Go to original source... Go to PubMed...
    10. Feltl D. Potřebujeme radioterapii v léčbě Hodgkinovy choroby? Klin. Onkol 2003; 16: 184-186.
    11. Jones E, Mauch P. Limited radiation therapy for selected patients with stage IA and IIA Hodgkin´s disease. Semin Radiation Oncol 1996; 6: 162-171. Go to original source...
    12. Biti G, Cimino G, Bartoni C, et al. Extended-field radiotherapy is superior toMOPP chemotherapy of pathologic stage I-IIA Hodgkin´s disease: eight-year update of an Italian prospective randomized study. J Clin Oncol 1992; 10: 378-382. Go to original source... Go to PubMed...
    13. Kaplan HD. Hodgkin´s disease. Harvard University Press, Cambridge 1980.
    14. Hancock L, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin´s disease. JAMA, 1993; 270: 1949-1955. Go to original source...
    15. Mauch PM, Kalish LA, Marcus KC, et al. Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome. Blood. 1996; 87(9): 3625-3632. Go to original source...
    16. Duhmke E, Franclin J, Preundschuh M, et al. Low-dose radiation is sufficient for the non involved extended-field treatment in favourable early-stage Hodgkin´s disease: long-term results of a randomized trial of radiotherapy alone. J Clin Oncol 2001; 19: 2905-2914. Go to original source... Go to PubMed...
    17. Horning S, Hoppe RT, Hancock SL, et al. Vinblastine, bleomycine and methotrexate: an effective adjuvant in favourable Hodgkin´s disease. J Clin Oncol 1988; 6: 1822-1831. Go to original source... Go to PubMed...
    18. Radfort JA, Copan RA, Ryder WDJ. Four weeks of neo-adjuvant chemotherapy significantly reduces the progression rate in patients treated with limited field radiotherapy for clinical stage IA/IIA Hodgkin´s disease. Results of a randomized pilot study. Ann Oncol 1996; 7: 66.
    19. Hagenbeek A, Carde P, Noordijk E, et al. Prognostic factor tailored treatment of early stage Hodgkin´s disease. Results from a prospective randomized phase III clinical trial in 762 patients (H7 study). Blood, 1997; 90(Suppl): 2603.
    20. Valagussa P, Santoro A, Fossati-Bellani F, et al. Second acute leukemia and other malignancies following treatment for Hodgkin´s disease. J Clin Oncol 1986; 4: 830-837. Go to original source... Go to PubMed...
    21. Kulkarni SS, Sastry PS, Saikia TK, et al. Gonadal function following ABVD therapy for Hodgkin's disease. Am J Clin Oncol 1997; 20(4): 354-357. Go to original source... Go to PubMed...
    22. Marmor D, Duyck F. Male reproductive potential after MOPP therapy for Hodgkin's disease: a long-term survey. Andrologia, 1995; 27(2): 99-106. Go to original source... Go to PubMed...
    23. Bates NP, Williams MW, Vaughan HG, et al. Efficacy and toxicity of vinblastine, bleomycine, and methotrexate with involved-field radiotherapy in clinical stage IA and IIA Hodgkin´s disease: A British national lymphoma Investigation pilot study. J Clin Oncol 1994; 12: 288-296. Go to original source... Go to PubMed...
    24. Engert A, Diehl V, Emeritus A, et al. Two Cycles of ABVD Followed by Involved Field radiotherapy with 20 Gy Is the New Standard of care in the Treatment of Patients with EarlyStage Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group (GHSG) HD 10. Blood 2009; 114: 299, abst. 716. Go to original source... Go to PubMed...
    25. Fermé C, Eghbali H, Meerwaldt J, et al. Chemotherapy plus Involved-Field Radiation in Early-Stage Hodgkin´s Disease. N. Engl. J. Med. 2007; 357: 1916-1927. Go to original source... Go to PubMed...
    26. Zittun R, Audebert A, Hoerni B, et al. Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin´s disease. J Clin Oncol 1985; 3: 207-214. Go to original source... Go to PubMed...
    27. Santoro A, Bonifante V, Viviani S, et al. Subtotal nodal (STNI) vs. Involved field (IFRT) irradiation after 4 cycles of ABVD in early stage Hodgkin´s disease. Proc Am Soc Clin Oncol 1996; 15: 1271.
    28. Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavourable Hodgkin´s lymphoma: results of the HD8 trial of the German Hodgkin´s Lymphoma Study Group. J Clin Oncol 2003; 21: 3601-3608. Go to original source... Go to PubMed...
    29. Borchmann P, Engert A, Pluetschow A, et al. Dose-Intensified Combined Modality Treatment with 2 Cycles BEACOPP Escalated Followed by 2 Cycles of ABVD and IF-RT in Patients with Early Unfavourable Hodgkin lymphoma: An Analysis of the German Hodgkin Study Group (GHSG) HD 14. Blood 2008; 112: 143, abst. 367. Go to original source...
    30. Moxley JH III, De Vita VT, Brace K, et al. Intensive combination chemotherapy and X-irradiation in Hodgkin's disease. Cancer Res, 1967; 27: 1258-1263.
    31. Jacobs C, Portlock C, Rosenberg S. Prednison in MOPP chemotherapy for Hodgkin´s disease. Br Med J, 1976; 2: 1469-1471. Go to original source... Go to PubMed...
    32. Devita VT Jr, Serpick AA, Karbone PP. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med, 1970; 73: 881-895. Go to original source... Go to PubMed...
    33. Longo DL, Zouny RC, Wesley M, et al. Twenty years of MOPP chemotherapy for Hodgkin´s disease. J Clin Oncol, 1986; 4: 1295-1306. Go to original source... Go to PubMed...
    34. Bonadonna G, Zucali R, Monfardini S, De Lena M, et al. Combination chemotherapy of Hodgkin´s disease with adriamycine, bleomycine, vinblastine, and imidazol carboximide versus MOPP. Cancer, 1975; 36: 252-259. Go to original source...
    35. Tucker MA, Coleman CN, Cox RS, et al. Risk of second cancer after treatment for Hodgkin´s disease. N Engl J Med, 1988; 318: 76-81. Go to original source... Go to PubMed...
    36. Bonadonna G, Valagussa P, Santoro A, et al. Hodgkin's disease: the Milan Cancer Institute experience with MOPP and ABVD. Recent Results Cancer Res. 1989; 117: 169-174. Go to original source... Go to PubMed...
    37. Santoro A, Bonadonna G, Valagussa P, et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 1987; 5: 27-37. Go to original source... Go to PubMed...
    38. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992; 327(21): 1478-1484. Go to original source... Go to PubMed...
    39. Goldie JH, Coldman AJ. A mathematical model for relating the druha sensitivity of tumors to the spontaneous mutation rate. Cancer Treat Rep, 1979; 63: 1727-1733. Go to PubMed...
    40. Connors JM, Klimko P, Adams G, et al. Treatment of advanced Hodgkin´s disease with chemotherapy-comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: A report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1997; 15: 1638-1645. Go to original source... Go to PubMed...
    41. Culen MH, Start NSA, Woodroffe C, et al. ChlVPP/PAB1OE and radiotherapy in advanced stage Hodgkin´s disease. J Clin Oncol 1994; 12: 779-787. Go to original source... Go to PubMed...
    42. Hancock BW, Vaughan Hudson G, Vaughan Hudson B, et al. LOPP alternating with EVAP is superior to LOPP alone in the initial treatment of advanced Hodgkin´s disease: results of a British national Lymphoma Investigation trial. J Clin Oncol 1992; 10: 1252-1258. Go to original source... Go to PubMed...
    43. Longo DL, Duffey PL, DeVita VT Jr, et al. Treatment of advanced-stage Hodgkin´s disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP. J Clin Oncol, 1991; 9: 1409-1420. Go to original source... Go to PubMed...
    44. Josting A, Franclin J, May M, et al. New prognostic score based on treatment outcome of Hodgkin´s Lymphoma Study Group. J Clin Oncol 2002; 20: 221-230. Go to original source...
    45. Bonifante V, Santoro A, Viviani S, et al. Outcome of patients with Hodgkin´s disease failing after primary MOPP-ABVD. J Clin Oncol 1997; 15: 528-534. Go to original source... Go to PubMed...
    46. Marková J, Kocová J, Malinová B, et al. Léčba Hodgkinovy choroby podle protokolu Německé studijní skupiny. Naše zkušenosti a výsledky. Vnitř. Lék., 2000; 46(4): 225-231.
    47. Marková J. Nové strategie v léčbě Hodgkinovy choroby (Studijní setkání Deutsche Hodgkin Lymphom Studiengruppe, Kolín nad Rýnem, červen 1997. Klin. Onkol. 1998; 11: 99-100.
    48. Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med, 1985; 102: 596-602. Go to original source... Go to PubMed...
    49. Horning SJ, Hoppe RT, Breslin S, et al. Locally Extensive and Advanced Hodgkin's Disease: Mature Results of a Prospective Clinical Trial. J Clin Oncol 2002; 20: 630-637. Go to original source...
    50. Engert A, Diehl V, Franklin J, el al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin´s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 2009; 27: 4548-4554. Go to original source... Go to PubMed...
    51. Diehl V, Franclin J, Pfreundshuh M, et al. Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin´s disease. N Engl J Med, 2003; 348: 2386-2395. Go to original source... Go to PubMed...
    52. Diehl V, Sieber M, Ruffer U, et al. BEACOPP: an intensified chemotherapy regiment in advaced Hodgkin´s disease. Ann Oncol 1997; 8: 143-148. Go to original source... Go to PubMed...
    53. Tesech H, Diehl V, Nathan B, et al. Moderate dose escalation for advanced stage Hodgkin´s disease the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and predinisone scheme and adjuvant radiotherapy: a study of German Hodgkin´s Lymphoma Study Group. Blood, 1998; 92: 4560-4567. Go to original source...
    54. Diehl V, Franklin J, Haseclever D, et al. BEACOPP. a new dose-escalated and accelerated regiment, is at lest as effective as COPP/ABVD in patients with advanced-stage Hodgkin´s lymphoma: interim report from a trial of the German Hodgkin´s Lymphoma Study Group. J Clin Oncol 1998; 126: 3810-3821. Go to original source... Go to PubMed...
    55. Diehl V, Franklin J, Paulu U, et al. BEACOPP chemotherapy impruves survival, and dose escalation further improves tumor control in advanced stage Hodgkin´s disease: GHSG HD9 results. Leuk Lymphoma, 2001; 42(suppl 2): 16.
    56. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomized trial. Lancet 2002; 359: 2065-2071. Go to original source... Go to PubMed...
    57. Linch DC, Golgstone AH, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin´s disease: results of a BNLI randomized trial. Lancet 1993; 341: 1051-1054. Go to original source... Go to PubMed...
    58. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin´s disease. N Engl J Med, 1988; 339: 1506-1514. Go to original source... Go to PubMed...
    59. Moskowitz CH, Kewalramani T, Nimer SD, et al. Effectiveness of high dose chemo-radiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 2004; 124: 645-652. Go to original source... Go to PubMed...
    60. Gopal AK, Metcalfe TL, Gooley TA, et al. High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: The Seattle experience. Cancer 2008; 113: 1344-1350. Go to original source... Go to PubMed...
    61. Fung HC, Stiff P, Schriber J, et al. Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma. Biol Blood Marrow Transplant 2007; 13: 594-600. Go to original source... Go to PubMed...
    62. Brice P, Divine M, Simon D, et al. SFGM/GELA Study Group. Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavourable (UF) relapse from Hodgkin's disease (HD). Ann Oncol 1999; 10: 1485-1488. Go to original source... Go to PubMed...
    63. Sureda A, Robinson S, Canals C, et al. Reduced-intensity conditioning compared with conventional allogeneic stemcell transplantation in relapsed or refractory Hodgkin's lymphoma: An analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008; 26: 455-462. Go to original source... Go to PubMed...
    64. Thomson KJ, Peggs KS, Smith P, et al. Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation. Bone Marrow Transplant 2008; 41: 765-770. Go to original source... Go to PubMed...
    65. Younes A, Forero-Tores A, Bartlett NL, et al. Multiple complete responses in a phase 1 dose escalation study of the antibody-drug conjugate SGN-35 in patients with relapsed or refractory CD30-positive lymphomas. Blood 2008; 112: 370. Go to original source...
    66. Oki Y, Pro B, Fayad LE, et al. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer 2008; 112: 831-836. Go to original source... Go to PubMed...
    67. Trelle S, Sezer O, Naumann R, et al. Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: Results of a prematurely closed phase II study (NCT00148018). Haematologica 2007; 92: 568-569. Go to original source... Go to PubMed...
    68. Younes A, Fanale M, Pro B, et al. A phase II study of a novel oral isotope-selective histone deacetylase (HDAC) inhibitor in patients with relapsed or refractory Hodgkin lymphoma. J Clin Oncol 2007; 25(18 suppl): 8000. Go to original source...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.